| Autor: |
Claudia Parisi, José Carlos Benitez, Hélène Lecourt, Filippo Gustavo dall’Olio, Mihaela Aldea, Felix Blanc-Durand, Véronique Vergé, Cyril Quivoron, Charles Naltet, Pamela Abdayem, Pernelle Lavaud, Maria Rosa Ghigna, Luc Friboulet, Yohann Loriot, Stéphane De Botton, Vincent Ribrag, Andrea Ardizzoni, David Planchard, Jean-Charles Soria, Fabrice Barlesi, Benjamin Besse |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
The Journal of Liquid Biopsy, Vol 6, Iss , Pp 100164- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2950-1954 |
| DOI: |
10.1016/j.jlb.2024.100164 |
| Popis: |
Importance: Deregulation of anaplastic lymphoma kinase (ALK) occurs in 3–7% of advanced NSCLC mainly because of chromosomic rearrangements at the ALK locus. Next to its oncogenic function, ALK chimeric oncoprotein is a possible antigen for human immune system. The prognostic value of natural anti-ALK immunogenicity remains poorly explored in ALK + NSCLC. We hereby report preliminary results of a plasmatic anti-ALK a-abs titration assessment in a cohort of ALK + NSCLC pts. Objective: To evaluate the prevalence of pre-existing circulating anti-ALK a-abs in ALK + NSCLC pts. Key secondary objectives are the assessment of anti-ALK a-abs prognostic value and association with brain metastases (BM). Design: This monocentric case series included 60 ALK + NSCLC pts progressing on any anti-ALK TKIs between October 2015 and February 2021 at Gustave Roussy Cancer Campus. Fifty-six plasma samples were analyzed through a semiquantitative immunocytochemical technique. Plasma samples were obtained from two prospective studies approved by our Institutional Review Board: the MATCH-R trial (NCT02517892) and the MSN trial (RECF1256). Participants: We included pts diagnosed with unresectable stage III or IV NSCLC, either by contemporaneous or historical biopsy. ALK-rearrangement was identified by FISH, IHC or NGS. Pts were aged more than 18-year-old and had previously signed informed consent for one of the studies. Pts had received at least one anti-ALK-TKI during the disease history. Pts were not eligible if they had been diagnosed with a second cancer. Main outcomes and measures: The prevalence of plasmatic anti-ALK a-abs titer was reported as percentage. Progression-free survival, overall survival, and time to BM were analyzed using Kaplan-Meier methods. Results: We found an anti-ALK a-abs titer in 5 (9 %) pts. anti-ALK a-abs did not contribute to prolongation of survival. Although not significant, there was a trend towards protection against BM in the presence of anti-ALK a-abs. Conclusions and relevance: Because ALK fusion proteins are exclusively produced intracellularly, not all ALK autoantibodies may have direct anti-tumor impact with favorable prognostic value. This is the first investigation to explore the impact of circulating anti-ALK a-abs on BM. Prospective studies with longer follow-up are warranted to further explore the impact of anti-ALK a-abs on BM. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
